Draft guidance from NICE rejects the use of Tegsedi in hereditary transthyretin-related amyliodsis.- Akcea Therapeutics.
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for Tegsedi (inotersen), from Akcea Therapeutics, to treat the inherited condition hereditary transthyretin-related amyliodsis.
Preliminary highly specialised technologies guidance concluded that the therapy offers short term benefits for people with the condition by slowing disease progression and improving quality of life. However, it is uncertain whether these benefits are maintained in the longer-term. As a result cost-effectiveness estimates are much higher than the range that can be considered an appropriate use of NHS resources for highly specialised services.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.